{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000112","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.128077+00:00","generated_at":"2026-06-07T02:47:08.707499+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCryst announces FY2023 ORLADEYO revenue $325M (+29%), 2024 guidance $380-400M, sees operating profit in 2024","bullets":["Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).","2024 ORLADEYO revenue guidance $380-400M; company reaffirms peak sales target of $1B.","2024 operating expenses expected flat at $365-375M; R&D reduced $20M vs 2023.","Restructuring reduces workforce by 59 jobs (10%); plans to out-license BCX10013 if data supports.","ORLADEYO WAC increased ~5% to $42,366 per 28-day pack, effective January 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000112","json":"https://secwatch.observer/filing/0001171843-24-000112.json","markdown":"https://secwatch.observer/filing/0001171843-24-000112.md","text":"https://secwatch.observer/filing/0001171843-24-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/0001171843-24-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/f8k_010824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:47:08.707499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f777079c43b3fda7dce13202084c8ef39de5a56c","claim":"BIOCRYST PHARMACEUTICALS INC reported full year 2024 results: revenue 380-400. Guidance reaffirmed.","evidence_excerpt":"Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expected to remain flat ($365-$375 million) in 2024— —Company expects operating profit in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/0001171843-24-000112-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"380-400"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}